Skip to main content


Paxvax Inc. based in Redwood City, California, was formerly a company focused on the development of specialty vaccines to protect against existing and emerging infectious diseases.

In August 2018, PaxVax Inc. was acquired by Emergent BioSolutions, Inc. headquartered in Gaithersburg, Maryland. With the acquisition of Paxvax, Emergent BioSolutions acquired Vivotif oral vaccine for the prevention of typhoid fever, Vaxhora vaccine for the prevention of cholera, and several clinical-stage vaccine candidates.

See: Emergent BioSolutions Inc.